search
Back to results

Minimal Invasive Procedure for Myocardial Infarction (MIMI)

Primary Purpose

ST Elevation Myocardial Infarction

Status
Completed
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
MIMI procedure (two-step strategy)
Immediate Stenting (one-step strategy)
Sponsored by
Centre Hospitalier Annecy Genevois
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ST Elevation Myocardial Infarction focused on measuring Acute STEMI, Thrombus aspiration, Angioplasty, Primary Percutaneous Coronary Intervention

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with acute STEMI presenting within 12 hours of symptom onset, requiring a primary percutaneous coronary intervention; and written informed consent.
  • Patients will be randomized during the angiography if the initial TIMI flow is 0 or 1 in a major artery and if TIMI-3 flow can be restored after thrombus aspiration and sustained for 10 minutes.
  • Acute STEMI is defined as typical chest pain with 30 minutes of sustained ST-segment elevation >1 mm in two or more consecutive limb leads or >2 mm in two or more precordial leads in the ECG. Major artery is defined as the proximal or mid segment of the left descending artery, the proximal segment of the circumflex artery (before the first marginal), or the right coronary artery before the posterior descendant artery.

Exclusion Criteria:

  • Patients less than 18 years' old
  • Pregnant and breast feeding women
  • Patients with a pacemaker, automated implantable cardioverter-defibrillator (AICD), or left bundle branch block
  • Contraindication to abciximab, prasugrel, or clopidogrel
  • Cardiac arrest as initial presentation
  • Current medical condition with a life expectancy of < 6 months
  • Patients not living in France
  • Patients in cardiogenic shock
  • Culprit artery <2.5 mm
  • Absence of informed consent
  • Patients with initial TIMI 2 or 3 flow or no TIMI-3 flow restored after thrombus aspiration
  • Rescue PCI after fibrinolysis
  • Known creatinine clearance < 30 ml/min.

Sites / Locations

  • CHRA
  • Hopital Privé
  • Ch Bastia
  • Clinique Convert
  • CH
  • CH
  • CHU
  • CHU
  • CHU Nord
  • Clinique Mutualiste
  • CHU
  • CH St Luc St Joseph
  • CHU Croix Rousse
  • Clinique du Tonkin
  • CHU Nord
  • CHI
  • Clinique Marie Lannelongue
  • CH
  • Clinique de Courlancy
  • Clinique St Hilaire
  • CHU
  • Clinique St Gatien
  • CH
  • CH

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

MIMI procedure (two-step strategy)

Immediate Stenting (one-step strategy)

Arm Description

Thrombus aspiration is performed to achieve TIMI-3 flow. Once TIMI-3 flow is restored and sustained for > 10 minutes, the initial procedure is stopped regardless of the presence of any residual stenosis. A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.

The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).

Outcomes

Primary Outcome Measures

The primary endpoint is the extent of MVO as assessed by CMRI, expressed as the ratio of MVO/left ventricular mass, in the MIMI and conventional groups.
The primary end-point will be reviewed by an independent CMRI core laboratory blinded to the group and the procedure. MVO is defined as a hypoenhanced subendocardial area in the infarction core 2 or 10 minutes after contrast injection (dark zone). The total myocardial infarction is defined as the sum of hypoenhanced (dark zone) and hyperenhanced (white zone) signals 10 minutes after contrast injection. The CMRI procedure will be standardised with a specific documentation.

Secondary Outcome Measures

Comparison of the MIMI approach and the conventional strategy on TIMI flow, myocardial blush, and ST-segment evolution before and after the first procedure.
Measurements: TIMI flow grade and TIMI frame count (a more sophisticated method for measuring the flow) at the end of the procedure; blush (a more precise evaluation than TIMI flow on angiography); and ST-segment evolution on the electrocardiogram (ECG) before and 60-90 minutes after the first procedure (core laboratory).
To measure TIMI flow and myocardial blush at the beginning and at end of the second procedure in the MIMI group, and to compare with those obtained at the end of the first procedure.
Measurements: TIMI flow grade, TIMI frame count, and blush at the beginning and at the end of the second procedure.
Thrombus burden assessment, and culprit artery diameter between each procedure in the MIMI group
Measurements: Thrombus volume and artery diameter at the thrombus location during the first and second procedure, and diameter of the implanted stent (done at the core laboratory).
Assessment of the ST-segment after the second procedure in the MIMI group
Measurements: Maximal ST-segment elevation before and 60-90 minutes after the second procedure (done at the core laboratory).
Assessment of the impact of the MIMI procedure on hospital clinical events, infarction size (on CMRI) and complications due to the second procedure.
The following hospital critical events and complications that occur after the first procedure will be analyzed: cardiogenic shock, acute pulmonary oedema, recurrent myocardial infarction, culprit artery re-occlusion, stroke, major bleeding [Bovill et al. 1991], evaluation of no flow, coronary dissection, recurrent myocardial infarction, chest pain, decelerating angio flow, recurrent ST elevation, troponin elevation, severe renal insufficiency, access site bleeding, and access artery occlusion. Measurement: CMRI infarction size.
Assessment of the clinical impact of the MIMI procedure at 6 months
Measurements: In both groups, follow-up will be undertaken at 6 months by a phone call to the general practitioner, cardiologist or patient, to report the occurrence of: death, recurrent myocardial infarction, hospitalization(s) for cardiac insufficiency, and unscheduled revascularisation.
Assessment of the microcirculatory resistance in patients in whom a pressure endocoronary wire was used.
Measurement: Index of microcirculatory resistance (IMR) just after stenting (first procedure for the conventional group and second procedure for the MIMI group)
Hospitalization duration for both procedures
Measurements: Number of days in ICU

Full Information

First Posted
April 28, 2011
Last Updated
March 5, 2015
Sponsor
Centre Hospitalier Annecy Genevois
Collaborators
University Hospital, Grenoble
search

1. Study Identification

Unique Protocol Identification Number
NCT01360242
Brief Title
Minimal Invasive Procedure for Myocardial Infarction
Acronym
MIMI
Official Title
Patients Presenting With Acute STEMI Treated With Primary PCI : Comparison of the Impact of the MIMI Approach With a Conventional Strategy of Immediate Stenting
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
June 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Annecy Genevois
Collaborators
University Hospital, Grenoble

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In the setting of primary Percutaneous Coronary Intervention (PCI), the investigators hypothesize that a 24-48 hour delay strategy of stenting after successful thrombus aspiration and establishment of Thrombolysis In Myocardial Infarction (TIMI)-3 flow with optimal antithrombotic therapy may decrease the risk of MicroVascular Obstruction (MVO) as assessed by Cardiac Magnetic Resonance Imaging (CMRI).
Detailed Description
Primary PCI is the reperfusion therapy of choice in patients with acute ST-elevation myocardial infarction (STEMI) [Van de Werf et al. 2008; Kushner et al. 2009]. The first objective in primary PCI is to restore TIMI-3 flow. However, despite restoration of TIMI-3 flow, myocardial reperfusion remains suboptimal in a significant proportion of patients, predominantly as a consequence of the so called "myocardial non-reperfusion phenomenon", "low/no-reflow phenomenon" or MVO. This, in turn, is associated with significant morbidity and mortality [Brodie et al. 2005; Bruder et al. 2008; Hombach et al. 2005; Nijveldt et al. 2008; Thiele et al. 2008; Wu et al. 1998]. Although TIMI flow is well assessed by angiography, contrast-enhanced CMRI remains the gold standard in the assessment of MVO. Indeed, the presence and extent of hypoenhanced areas have been shown to be associated with a poor outcome [Bruder et al. 2008; Hombach et al. 2005; Nijveldt et al. 2008; Wu et al. 1998]. There is now a large body of evidence to suggest that even in patients with TIMI-3 flow on angiography, as many as 60% of these patients will subsequently exhibit MVO with CMRI [Brodie et al. 2005; Bruder et al. 2008; Hombach et al. 2005; Nijveldt et al. 2008; Thiele et al. 2008; Wu et al. 1998]. Our knowledge of the mechanisms of MVO occurrence as well as measures to reduce MVO has been considerably enhanced by recent publications. For instance, Sianos et al. [2007] demonstrated that the thrombus burden at the time of angiography is an independent predictor of MVO extension and 2-year mortality. Furthermore, Isaaz et al. [2006] recommended a two-step strategy as a means of minimising the risk of MVO, with the first step consisting of TIMI-3 flow restoration, followed 2-6 days later by further angiography to determine the therapeutic strategy of choice (PCI, cardiac surgery, or medical treatment: 67%, 25%, and 8% respectively). Meneveau et al. [2009] also adopted a two-step strategy in a small cohort of STEMI patients with TIMI-3 flow and ST-segment regression at the time of the procedure. They demonstrated that a 24-hour delay in stent implantation led to a higher rate of procedural success than immediate stenting. Isaaz et al. [2006] and Meneveau et al. [2009] also reported a decreased thrombus burden and no culprit-artery re-occlusion between the first and the second procedure. Both the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS) [Svilaas et al. 2008] and the thrombectomy with EXPort catheter in Infarct-Related Artery during primary percutaneous coronary intervention (EXPIRA) [Sardella et al. 2009] studies demonstrated the benefits of thrombus aspiration as the first step in primary PCI prior to either ballooning or direct stenting. However, as the effects of stenting upon MVO in the setting of acute STEMI remain poorly understood, we propose a randomized study to evaluate the benefits of a 24-48-hour delay in stent implantation compared to immediate stenting in patients presenting with acute STEMI who will undergo primary PCI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ST Elevation Myocardial Infarction
Keywords
Acute STEMI, Thrombus aspiration, Angioplasty, Primary Percutaneous Coronary Intervention

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
160 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MIMI procedure (two-step strategy)
Arm Type
Active Comparator
Arm Description
Thrombus aspiration is performed to achieve TIMI-3 flow. Once TIMI-3 flow is restored and sustained for > 10 minutes, the initial procedure is stopped regardless of the presence of any residual stenosis. A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
Arm Title
Immediate Stenting (one-step strategy)
Arm Type
Sham Comparator
Arm Description
The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
Intervention Type
Procedure
Intervention Name(s)
MIMI procedure (two-step strategy)
Other Intervention Name(s)
Delayed angioplasty, Two-step strategy
Intervention Description
A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
Intervention Type
Procedure
Intervention Name(s)
Immediate Stenting (one-step strategy)
Other Intervention Name(s)
Immediate Angioplasty
Intervention Description
The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
Primary Outcome Measure Information:
Title
The primary endpoint is the extent of MVO as assessed by CMRI, expressed as the ratio of MVO/left ventricular mass, in the MIMI and conventional groups.
Description
The primary end-point will be reviewed by an independent CMRI core laboratory blinded to the group and the procedure. MVO is defined as a hypoenhanced subendocardial area in the infarction core 2 or 10 minutes after contrast injection (dark zone). The total myocardial infarction is defined as the sum of hypoenhanced (dark zone) and hyperenhanced (white zone) signals 10 minutes after contrast injection. The CMRI procedure will be standardised with a specific documentation.
Time Frame
day of performing CMRI (between the fourth and the seventh day after randomization)
Secondary Outcome Measure Information:
Title
Comparison of the MIMI approach and the conventional strategy on TIMI flow, myocardial blush, and ST-segment evolution before and after the first procedure.
Description
Measurements: TIMI flow grade and TIMI frame count (a more sophisticated method for measuring the flow) at the end of the procedure; blush (a more precise evaluation than TIMI flow on angiography); and ST-segment evolution on the electrocardiogram (ECG) before and 60-90 minutes after the first procedure (core laboratory).
Time Frame
before and 60-90 minutes after the first procedure
Title
To measure TIMI flow and myocardial blush at the beginning and at end of the second procedure in the MIMI group, and to compare with those obtained at the end of the first procedure.
Description
Measurements: TIMI flow grade, TIMI frame count, and blush at the beginning and at the end of the second procedure.
Time Frame
at the beginning and one minute after the end of the second procedure
Title
Thrombus burden assessment, and culprit artery diameter between each procedure in the MIMI group
Description
Measurements: Thrombus volume and artery diameter at the thrombus location during the first and second procedure, and diameter of the implanted stent (done at the core laboratory).
Time Frame
during each procedure (0-48 hours)
Title
Assessment of the ST-segment after the second procedure in the MIMI group
Description
Measurements: Maximal ST-segment elevation before and 60-90 minutes after the second procedure (done at the core laboratory).
Time Frame
at the beginning (puncture) and 60-90 min after the end of the second procedure
Title
Assessment of the impact of the MIMI procedure on hospital clinical events, infarction size (on CMRI) and complications due to the second procedure.
Description
The following hospital critical events and complications that occur after the first procedure will be analyzed: cardiogenic shock, acute pulmonary oedema, recurrent myocardial infarction, culprit artery re-occlusion, stroke, major bleeding [Bovill et al. 1991], evaluation of no flow, coronary dissection, recurrent myocardial infarction, chest pain, decelerating angio flow, recurrent ST elevation, troponin elevation, severe renal insufficiency, access site bleeding, and access artery occlusion. Measurement: CMRI infarction size.
Time Frame
from randomisation to an expected average 4 days stay before hospital discharge
Title
Assessment of the clinical impact of the MIMI procedure at 6 months
Description
Measurements: In both groups, follow-up will be undertaken at 6 months by a phone call to the general practitioner, cardiologist or patient, to report the occurrence of: death, recurrent myocardial infarction, hospitalization(s) for cardiac insufficiency, and unscheduled revascularisation.
Time Frame
6 months after randomization
Title
Assessment of the microcirculatory resistance in patients in whom a pressure endocoronary wire was used.
Description
Measurement: Index of microcirculatory resistance (IMR) just after stenting (first procedure for the conventional group and second procedure for the MIMI group)
Time Frame
after each procedure (0-48 hours)
Title
Hospitalization duration for both procedures
Description
Measurements: Number of days in ICU
Time Frame
expected average time from randomisation to Intensive Care Unit (ICU) discharge of 4 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with acute STEMI presenting within 12 hours of symptom onset, requiring a primary percutaneous coronary intervention; and written informed consent. Patients will be randomized during the angiography if the initial TIMI flow is 0 or 1 in a major artery and if TIMI-3 flow can be restored after thrombus aspiration and sustained for 10 minutes. Acute STEMI is defined as typical chest pain with 30 minutes of sustained ST-segment elevation >1 mm in two or more consecutive limb leads or >2 mm in two or more precordial leads in the ECG. Major artery is defined as the proximal or mid segment of the left descending artery, the proximal segment of the circumflex artery (before the first marginal), or the right coronary artery before the posterior descendant artery. Exclusion Criteria: Patients less than 18 years' old Pregnant and breast feeding women Patients with a pacemaker, automated implantable cardioverter-defibrillator (AICD), or left bundle branch block Contraindication to abciximab, prasugrel, or clopidogrel Cardiac arrest as initial presentation Current medical condition with a life expectancy of < 6 months Patients not living in France Patients in cardiogenic shock Culprit artery <2.5 mm Absence of informed consent Patients with initial TIMI 2 or 3 flow or no TIMI-3 flow restored after thrombus aspiration Rescue PCI after fibrinolysis Known creatinine clearance < 30 ml/min.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Loic BELLE, MD
Organizational Affiliation
Centre Hospitalier Annecy Genevois
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHRA
City
Annecy
Country
France
Facility Name
Hopital Privé
City
Antony
Country
France
Facility Name
Ch Bastia
City
Bastia
Country
France
Facility Name
Clinique Convert
City
Bourg En Bresse
Country
France
Facility Name
CH
City
Cannes
Country
France
Facility Name
CH
City
Chambery
Country
France
Facility Name
CHU
City
Clermont Ferrand
Country
France
Facility Name
CHU
City
Dijon
Country
France
Facility Name
CHU Nord
City
Grenoble
Country
France
Facility Name
Clinique Mutualiste
City
Grenoble
Country
France
Facility Name
CHU
City
Lille
Country
France
Facility Name
CH St Luc St Joseph
City
Lyon
Country
France
Facility Name
CHU Croix Rousse
City
Lyon
Country
France
Facility Name
Clinique du Tonkin
City
Lyon
Country
France
Facility Name
CHU Nord
City
Marseille
Country
France
Facility Name
CHI
City
Montfermeil
Country
France
Facility Name
Clinique Marie Lannelongue
City
Paris
Country
France
Facility Name
CH
City
Pontoise
Country
France
Facility Name
Clinique de Courlancy
City
Reims
Country
France
Facility Name
Clinique St Hilaire
City
Rouen
Country
France
Facility Name
CHU
City
St Etienne
Country
France
Facility Name
Clinique St Gatien
City
Tours
Country
France
Facility Name
CH
City
Valence
Country
France
Facility Name
CH
City
Vichy
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
1906692
Citation
Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991 Aug 15;115(4):256-65. doi: 10.7326/0003-4819-115-4-256.
Results Reference
background
PubMed Identifier
15670542
Citation
Brodie BR, Stuckey TD, Hansen C, VerSteeg DS, Muncy DB, Moore S, Gupta N, Downey WE. Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2005 Feb 1;95(3):343-8. doi: 10.1016/j.amjcard.2004.09.031.
Results Reference
background
PubMed Identifier
18344033
Citation
Bruder O, Breuckmann F, Jensen C, Jochims M, Naber CK, Barkhausen J, Erbel R, Sabin GV; Herzinfarktverbund Essen. Prognostic impact of contrast-enhanced CMR early after acute ST segment elevation myocardial infarction (STEMI) in a regional STEMI network: results of the "Herzinfarktverbund Essen". Herz. 2008 Mar;33(2):136-42. doi: 10.1007/s00059-008-3102-8.
Results Reference
background
PubMed Identifier
15713695
Citation
Hombach V, Grebe O, Merkle N, Waldenmaier S, Hoher M, Kochs M, Wohrle J, Kestler HA. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J. 2005 Mar;26(6):549-57. doi: 10.1093/eurheartj/ehi147. Epub 2005 Feb 15.
Results Reference
background
PubMed Identifier
16728877
Citation
Isaaz K, Robin C, Cerisier A, Lamaud M, Richard L, Da Costa A, Sabry MH, Gerenton C, Blanc JL. A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention. Coron Artery Dis. 2006 May;17(3):261-9. doi: 10.1097/00019501-200605000-00010.
Results Reference
background
PubMed Identifier
19923169
Citation
Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009 Dec 1;120(22):2271-306. doi: 10.1161/CIRCULATIONAHA.109.192663. Epub 2009 Nov 18. No abstract available. Erratum In: Circulation. 2010 Mar 30;121(12):e257. Dosage error in article text.
Results Reference
background
PubMed Identifier
19205776
Citation
Meneveau N, Seronde MF, Descotes-Genon V, Dutheil J, Chopard R, Ecarnot F, Briand F, Bernard Y, Schiele F, Bassand JP. Immediate versus delayed angioplasty in infarct-related arteries with TIMI III flow and ST segment recovery: a matched comparison in acute myocardial infarction patients. Clin Res Cardiol. 2009 Apr;98(4):257-64. doi: 10.1007/s00392-009-0756-z. Epub 2009 Feb 9.
Results Reference
background
PubMed Identifier
18617066
Citation
Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR, Twisk JW, van Rossum AC. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol. 2008 Jul 15;52(3):181-9. doi: 10.1016/j.jacc.2008.04.006.
Results Reference
background
PubMed Identifier
19161878
Citation
Sardella G, Mancone M, Bucciarelli-Ducci C, Agati L, Scardala R, Carbone I, Francone M, Di Roma A, Benedetti G, Conti G, Fedele F. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009 Jan 27;53(4):309-15. doi: 10.1016/j.jacc.2008.10.017.
Results Reference
background
PubMed Identifier
17692740
Citation
Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007 Aug 14;50(7):573-83. doi: 10.1016/j.jacc.2007.04.059. Epub 2007 Jul 30.
Results Reference
background
PubMed Identifier
18256391
Citation
Svilaas T, Vlaar PJ, van der Horst IC, Diercks GF, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES, Suurmeijer AJ, Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008 Feb 7;358(6):557-67. doi: 10.1056/NEJMoa0706416.
Results Reference
background
PubMed Identifier
18559698
Citation
Thiele H, Schindler K, Friedenberger J, Eitel I, Furnau G, Grebe E, Erbs S, Linke A, Mobius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.
Results Reference
background
PubMed Identifier
19004841
Citation
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008 Dec;29(23):2909-45. doi: 10.1093/eurheartj/ehn416. Epub 2008 Nov 12. No abstract available.
Results Reference
background
PubMed Identifier
9498540
Citation
Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998 Mar 3;97(8):765-72. doi: 10.1161/01.cir.97.8.765.
Results Reference
background
PubMed Identifier
26957418
Citation
Belle L, Motreff P, Mangin L, Range G, Marcaggi X, Marie A, Ferrier N, Dubreuil O, Zemour G, Souteyrand G, Caussin C, Amabile N, Isaaz K, Dauphin R, Koning R, Robin C, Faurie B, Bonello L, Champin S, Delhaye C, Cuilleret F, Mewton N, Genty C, Viallon M, Bosson JL, Croisille P; MIMI Investigators*. Comparison of Immediate With Delayed Stenting Using the Minimalist Immediate Mechanical Intervention Approach in Acute ST-Segment-Elevation Myocardial Infarction: The MIMI Study. Circ Cardiovasc Interv. 2016 Mar;9(3):e003388. doi: 10.1161/CIRCINTERVENTIONS.115.003388.
Results Reference
derived

Learn more about this trial

Minimal Invasive Procedure for Myocardial Infarction

We'll reach out to this number within 24 hrs